Objective-The presence of kinase-insert domain-containing receptor (KDR) on circulating CD34
/KDR
ϩ cells are generated in the peripheral circulation. Methods and Results-Using an ex vivo flow model, we show that activated platelets enable CD34 ϩ cells to home to sites of vascular injury and that upon immobilization, KDR is translocated from an endosomal compartment to the cell-surface within 15 minutes. In patients with diabetes mellitus type 2, the percentage of circulating CD34 ϩ co-expressing KDR was significantly elevated compared to age-matched controls. When treated with aspirin, the patients showed a 49% reduction in the generation of CD34 ϩ /KDR ϩ cells, indicating that the level of circulating CD34 ϩ /KDR ϩ cells also relates to in vivo platelet activation.
Conclusion-Circulating CD34
ϩ /KDR ϩ are not mobilized from bone marrow as a predestined endothelial progenitor cell population but are mostly generated from circulating multipotent CD34 ϩ cells at sites of vascular injury. Therefore, the number of circulating CD34
ϩ /KDR ϩ cells may serve as a marker for vascular injury. ϩ /kinase-insert domain-containing receptor (KDR) ϩ cells and hemodynamic and metabolic cardiovascular risk factors, such as hypertension, hyperglycemia, hypercholesterolemia, and end-stage renal disease. 1 These circulating progenitor cells are considered to be a bone marrow (BM)-derived subpopulation of the CD34-positive hematopoietic stem cell fraction that coexpress vascular endothelial growth factor (VEGF) receptor type-2/KDR. 2 Because KDR expression is crucial for vascular development 3 
and isolated CD34
ϩ /KDR ϩ cells may contribute to reendothelialization, 4, 5 these cells are considered to play a role as endothelial progenitor cells in vascular maintenance and repair.
See accompanying article on page 243
Consequently, a reduced number of circulating CD34 ϩ / KDR ϩ cells was proposed to be a causal factor in the development of endothelial dysfunction and atherosclerosis. 6 Recently, we showed that hemostatic factors deposited at the site of an injury, such as activated platelets, platelet products, and fibrin, support the homing of human CD34 ϩ cells under flow. 7 The hemostatic clot provides local signals, such as P-selectin, stromal cell-derived factor-1/CXC-chemokine ligand-12 (SDF-1/CXCL12), and VEGF, which facilitated the arrest and survival of CD34 ϩ cells and induced their commitment toward an endothelial cell (EC)-like phenotype. 7 Given the importance of VEGF in endothelial differentiation, we investigated the dynamics of KDR expression by CD34 ϩ cells that have adhered to platelet-rich sites of EC activation under conditions of flow. Surprisingly, we observed that most, if not all, CD34
ϩ cells exhibit KDR expression within 15 minutes of shear exposure. Therefore, CD34
ϩ /KDR ϩ cells may not be mobilized from BM as a separate progenitor lineage but are predominantly generated from CD34 ϩ cells at sites of vascular injury. To address this hypothesis, we conducted a detailed ex vivo study of the early phenotypic changes that CD34 ϩ cells undergo after homing. We demonstrate that CD34 ϩ cells can rapidly translocate KDR from intracellular storage organelles to the cell surface in a regulated phosphatidylinositol-3-kinase (PI3K)-dependent pathway. Then, extensive analysis of the percentage of CD34 ϩ cells coexpressing KDR in BM, umbilical cord blood (UCB), and peripheral blood (PB) after G-CSF mobilization, in PB of control subjects and in vascular injury-prone patients with diabetese mellitus type 2 (DM2), also strongly supports the in vivo generation of CD34 ϩ /KDR ϩ cells in the periphery. Finally, to assess the role of platelets in the peripheral generation of CD34 ϩ /KDR ϩ cells in patients with DM2, we investigated the effect of aspirin (300 mg/d) in a placebo-controlled crossover study.
Methods
The supplemental material (available online at http://atvb.ahajournals. org) provides a full description of all methods.
Perfusions

Perfusions of CD34
ϩ cells were performed as previously described. 7
Subjects and Study Design
Circulating cells were studied in different samples: human BM, UCB, PB of G-CSF-stimulated healthy donors, PB of patients with DM2, and PB of age-matched control subjects. Subjects with DM were recruited from general practitioners affiliated with Leiden University Medical Center, Leiden, the Netherlands. Details about the randomized placebo-controlled study on the effect of aspirin in subjects with DM2 have been previously published. 8
Results
CD34
؉ Cells Homed to an EC Monolayer Under Shear Express KDR on Their Surface
Because platelet-derived VEGF signaling through KDR is one of the most likely drivers of EC differentiation 3 in vasculogenesis, we studied the dynamics of KDR expression by CD34 ϩ cells. On freshly isolated nonsheared CD34 ϩ (CD45 dim ) cells, KDR expression was not detectable above isotype (IT) levels ( Figure 1A ). When these cells were perfused in the ex vivo injury model, nonattaching CD34 ϩ cells (non) still lacked KDR expression, whereas recovered CD34 ϩ cells, which had been subjected to shear for 15 minutes (att, Figure 1A ) showed a significant surface expression of KDR (Pϭ0.042). As a control, both CD34 and P-selectin glycoprotein ligand-1 (PSGL-1) expression on nonsheared cells was confirmed ( Figure 1B [PϽ0.001] and Figure 1C [PϽ0.01], respectively) but was not altered on cells subjected to shear. KDR upregulation was observed on almost all recovered/sheared cells, as evident in the histogram in Figure 1F , which shows that the entire peak has shifted to the right compared with the level of IT-incubated CD34 ϩ cells (dashed line as a reference). For comparison, histograms are shown for KDR expression of nonperfused CD34 ϩ cells ( Figure 1D ) and nonattached cells after perfusion ( Figure 1E ). Immunohistochemical staining of the EC-adherent shearsubjected CD34
ϩ cells ( Figure 1H ) confirmed homogeneous expression of KDR on the cell surface ( Figure 1G ).
CD34
؉ Cells Harbor KDR in Intracellular Pools
After firm adhesion of CD34 ϩ to activated ECs, KDR was detectable after only 15 minutes of shear, suggesting the release from an intracellular storage pool rather than de novo synthesis. To demonstrate this, freshly isolated CD34 ϩ cells were fixed, permeabilized or not, and stained for the extracellular domain of KDR and CD34. IT-matched antibodies determined background levels. Indeed, KDR expression on naïve cells was only detectable after permeabilization ( Figure  1I , perm, PϽ0.01). In contrast, CD34 was not differentially expressed on permeabilized or nonpermeabilized cells (data not shown).
KDR Resides With CXC-Chemokine Receptor-4 (CXCR4 or SDF-receptor) in an Early Endosomal Compartment
Human CD34
ϩ cells harbor intracellular CXCR4 in an early endosomal compartment, which can be functionally expressed to mediate SDF-1-dependent homing. 9 To investigate whether KDR resides in similar structures, we studied colocalization of both KDR and CXCR4 with the early endosome marker-1 (EEA-1) in CD34 
Homed CD34
؉ Cells Mobilize KDR in a PI3K-Dependent Fashion On homing, CD34 cells are subjected to the injury-associated microenvironment, containing activated platelets and fibrin ( Figure 2A and 2B). Platelet-derived factors, in particular SDF-1, can signal through CXCR4 to initiate signal transduction pathways that prepare the cell for migration and differentiation. A common denominator of these pathways is the downstream activation of PI3K. 10 To investigate whether the translocation of KDR was the result of a PI3K-specific event, we visualized PI3K-dependent activation in these cells. First, adherent CD34 ϩ cells ( Figure 2D ) exhibited dense areas of polymerized filamentous actin (F-actin) in the cortical cytosol, demonstrating the activated status of the cells, which is secondary to PI3K-dependent activation involving Rac1, protein kinase C-, extracellular signal-regulated kinase 1/2, and WAVE2. 11 In contrast, nonsheared CD34 ϩ cells show diffuse low-level staining of F-actin ( Figure 2C) .
A second PI3K-dependent process that follows homing is the phosphorylation of Akt/PKB (p-Akt, protein kinase B). 12 Adherent cells showed a clear signal for p-Akt ( Figure 2E -2G) as opposed to the nonperfused control cells ( Figure 2C ). The presence of membrane-associated p-Akt at the contact sites of CD34 ϩ cells and ECs ( Figure 2F and 2G, different angles) again confirms that the CD34 ϩ cells are rapidly activated on firm adhesion. Next, we assessed whether the KDR translocation from the intracellular compartment to the cell surface is also dependent on PI3K activation. To that end, CD34
ϩ cells were preincubated with the PI3K inhibitor wortmannin (WM, 100 nmol/L) before and during perfusion, adherent cells were retrieved, and KDR expression was assessed by fluorescence-activated cell sorter (FACS). Inhibition of PI3K by WM showed a significantly reduced KDR signal ( Figure 1J ; ϩWM versus ϪWM; Pϭ0.03), whereas the signal obtained with the IT was not affected. The specific KDR expression, calculated by subtracting IT signals from the KDR signals (KDR-IT), revealed a decrease of 75% (PϽ0.01).
BM, UCB, or G-CSF-Mobilized PB Contains Low Levels of CD34
؉
/KDR
؉ Thus far, we demonstrated that few freshly isolated CD34 ϩ cells express KDR. We reasoned that CD34 ϩ /KDR ϩ cells might be generated in vivo at platelet-rich sites of vascular injury. This hypothesis predicts that the CD34 ϩ cell population, freshly recruited to the peripheral circulation of healthy subjects by mobilizing agents such as G-CSF, would contain low numbers of cells coexpressing KDR. In contrast, in patients with endothelial or ischemic injury, the percentage of CD34 ϩ cells coexpressing KDR would increase because of in vivo activation of the cells on the injured platelet-rich EC surface. To validate this hypothesis, we used a detailed quantitative FACS analysis of CD34 ϩ and CD34 ϩ /KDR ϩ cells. The FACS analysis was performed using a multipara- 
nonattached cells (E), and perfused/attached cells (F). IT binding is shown as background level (vertical dashed line). G and H, KDR expression on perfused and attached CD34
ϩ cells was analyzed using confocal laser scanning microscopy and showed homogeneous KDR expression on the cell surface (G), colocalizing with CD34 staining (H). Staining is combined with Nomarski projection (scale bar, 5 m). I, To show that KDR is localized in an intracellular pool, CD34 ϩ cells were fixed, either not permeabilized (nonperm) or permeabilized (perm), and stained for expression of KDR. IT controls were used to determine background staining. J, KDR expression on shear-subjected CD34 ϩ cells was reduced (Pϭ0.03) in the presence of the PI3K inhibitor WM (ϩWM vs ϪWM); this did not affect the MFI of IT controls. Subtraction of the IT signal (KDR-IT) from the KDR signal showed a reduction of KDR upregulation of 75% (PϽ0.01). In I, the overall MFI levels of KDR-staining and IT controls were higher vs those in A and J, probably because of fixation of the cells. metric gating strategy, including fluorescent microbeads, that permits the acquisition of absolute numbers of cells per volume of blood. However, because UCB is anticoagulated with a fixed amount of 8 mL of sodium citrate, the dilution of UCB samples may differ depending on the volume collected. Therefore, in this case, we expressed the number of CD34 Patients with DM2 may well display a vascular phenotype that is uniquely suited to study the correlation between vascular injury and circulating CD34 ϩ /KDR ϩ cells. The pathophysiological mechanisms involved in this chronic vascular disease include EC dysfunction, 13 ongoing vascular injury, 14 and increased platelet aggregability. 15 To investigate whether the number of circulating CD34 ϩ /KDR ϩ cells in patients at risk for chronic vascular disease relates to endothelial injury and platelet activation, we performed a randomized, double-blind, placebo-controlled crossover trial in patients with DM2. All subjects received placebo and aspirin (300 mg/d; nϭ20) for 6 weeks. The control subjects were originally included for a study on metabolic syndrome, for which hypertension, waist circumference, fasting blood glucose, triglyceride, and high-density lipoprotein cholesterol levels were defining variables. However, the control subjects only had 1 or 2 of these traits, whereas 3 or more traits are needed to define them as positive for metabolic syndrome. 16 Therefore, these subjects are considered excellent controls for the patients with diabetes, who had comparable ages and anthropometric indexes.
Subject characteristics are summarized in the Table, and statistical differences between the groups are shown with an asterisk. There were no differences in age, sex, and blood pressure (either systolic or diastolic). Patients with DM2 had a higher body mass index and waist circumference and elevated levels of fasting blood glucose, homeostasis model assessment of insulin resistance, glycohemoglobin, and C-reactive protein, indicating a low-grade inflammatory state. None of the statistical differences between groups disappeared when we restricted the analysis to male subjects with DM2 only (data not shown), indicating that these differences are consistent with the diabetic profile. Circulating cells were Figure 4B ). In agreement with our hypothesis, the percentage of circulating CD34 ϩ cells coexpressing KDR ϩ in the patients with DM2 at baseline was markedly elevated compared with the control group: in patients with DM2, 3.5%Ϯ0.8% of the circulating CD34 ϩ cells coexpressed KDR, which is 5-fold higher than the 0.7%Ϯ0.2% in the control group (Pϭ0.007, Figure 3 ).
CD34
؉
/KDR ؉ Cell Numbers Are Correlated With Plasma Levels of Soluble P-Selectin
To further support the role of platelets in the generation of CD34 ϩ /KDR ϩ in vivo, we compared the levels of soluble P-selectin (sP-sel) as a marker for in vivo platelet activation 17 in the placebo and aspirin-treated patients. Aspirin treatment did not affect the average values of sP-sel between the placebo and aspirin-treated groups (51.1Ϯ4.9 versus 54.3Ϯ6.0 ng/mL, respectively; Pϭ0.437; Figure 4C ). However, when looking at the subjects individually, 50% of the patients showed a reduction in sP-sel, whereas the other half showed increased sP-sel levels, confirming previous observations that the sensitivity for aspirin and, thus, the inhibition of in vivo basal platelet reactivity, in patients with DM2 is highly subject specific. 18 To investigate the relation between effective platelet aggregation inhibition and circulating cells, we calculated the increase or decrease (⌬ values) of sP-sel, CD34 ϩ , and CD34 ϩ /KDR ϩ cells for the individual patients and performed a linear regression analysis. As expected, changes in the number of CD34 ϩ cells did not correlate with changes in the level of sP-sel (Pϭ0.206, r 2 ϭ0.105, data not shown), indicating that CD34 ϩ cell numbers are not related to the degree of in vivo platelet activation. In contrast, ⌬ levels of CD34 ϩ / KDR ϩ cells were strongly correlated with ⌬ levels of sP-sel after aspirin treatment ( Figure 4D , PϽ0.001, r 2 ϭ0.589). Taken together, elevated platelet activation in patients with DM2 is strongly correlated with an increased number of circulating CD34 ϩ /KDR ϩ cells. Conversely, when platelet activation is inhibited, as in the "aspirin-responsive" patients with DM2, the number of circulating CD34 ϩ /KDR ϩ cells is reduced accordingly.
Discussion
Our study supports a novel concept for the origin of circulating CD34 ϩ /KDR ϩ cells ( Figure 5 ). In contrast to concepts that CD34 ϩ /KDR ϩ cells are mobilized from the BM as a unique predestined lineage with an endothelial fate, our data suggest that these cells more likely reflect the plasticity of CD34 ϩ cells and their capacity to respond to environmental cues. First, we determined that after G-CSF treatment, only 
0.19%Ϯ0.18% of the mobilized peripheral CD34
ϩ cells coexpress KDR. This level of expression is similar to that of the CD34 ϩ population in BM, which amounts to 0.34%Ϯ0.19% and confirms that during mobilization, little "activation" of these cells occurs. Second, we demonstrated that most, if not all, CD34
ϩ cells can rapidly upregulate KDR expression once recruited to platelet-and fibrin-rich EC surfaces. Third, in patients with DM2 who are known to display ongoing endothelial injury with associated platelet aggregation, we observed a 5-fold increase in the percentage of circulating CD34 ϩ cells coexpressing KDR compared with control subjects. Moreover, treatment with aspirin (300 mg/d) reduced the number of circulating CD34 ϩ /KDR ϩ cells by 47% in these patients, concomitant with markers of systemic platelet activation. Together, these data support our hypothesis that, also in vivo, CD34 ϩ /KDR ϩ cells are generated from CD34 ϩ cells at sites of vascular injury. We propose that most of the CD34 ϩ /KDR ϩ cells will remain associated with the vascular wall to participate in vascular repair ( Figure 5 ; arrow a), whereas a fraction of these cells may reenter the circulation from the injured vascular wall secondary to shear or mechanical stimuli ( Figure 5, arrow b) , thereby reflecting the rate of conversion of CD34 ϩ cells at platelet-rich sites of vascular injury. Thus, the number of CD34 ϩ /KDR ϩ cells may provide an index of systemic vascular injury.
Interestingly, in conditions of acute vascular ischemia and EC injury, an increase in the number of circulating CD34 ϩ / KDR ϩ cells has been observed (eg, thermal injury, 19 radiation-induced endothelial injury, 20 sepsis, 21 acute ischemic stroke, 22 acute myocardial infarction, 23 and even brief exposure to second-hand smoke 24 ). Some of these studies reported that the acute elevation of circulating CD34 ϩ /KDR ϩ cells was associated with a concomitant increase in levels of mobilizing factors, such as VEGF and SDF-1, suggesting a causal relationship. 21, 25 Furthermore, markers of endothelial damage/dysfunction (ie, von Willebrand factor and soluble E-selectin) and the platelet marker sP-sel 26 were reported to be elevated, suggesting that these acute conditions are associated with in vivo vascular injury and platelet activation. These data are in agreement with our concept that the CD34 ϩ /KDR ϩ cell fraction does not increase as a result of mobilization from BM but may rather be generated in the periphery from CD34
ϩ cells immobilized at platelet-rich sites of vascular injury.
We demonstrated that the absolute number of CD34 ϩ cells/per 10 3 CD45 ϩ leukocytes was significantly reduced in patients with DM2 compared with controls ( Figure 3 ). This is in line with many studies that have consistently demonstrated a reduction of these cells in patients with DM2 and in other patient groups with an increased risk for chronic vascular disease. 27 In contrast, we show that the percentage of CD34 ϩ cells coexpressing KDR is increased in patients with DM2; and this paralleled absolute numbers of these cells (data not shown). This seems contradictive to published results; however, in many reports, patients received aspirin 27 or platelet aggregation inhibitors, 28 and this may explain why these articles document lower amounts of CD34 ϩ /KDR ϩ cells in their patient cohorts.
The link between CD34 ϩ /KDR ϩ cell numbers and platelet activation in the patients with DM2 was only revealed when we distinguished patients who responded to aspirin from nonresponders. This may be explained by the fact that, in patients with coronary artery disease, diabetic patients have a high prevalence of laboratory-defined aspirin resistance. 18 Our ex vivo studies revealed that surface expression of KDR is already detectable within 15 minutes after adhesion to platelet-rich EC surfaces. This short time span indicates that KDR mobilization is not mediated by increased transcription, as was proposed in another model in which CD34 ϩ cells were subjected to shear for 24 hours. 29 Indeed, we detected an intracellular pool of KDR, associated with an EEA compartment, in which CXCR4 has also been localized. 9 Like other growth factor receptors, KDR 30 and CXCR4 9 are subject to a low constitutive rate of endocytosis. This internalization involves the formation of endocytic vesicles from clathrin-coated pits that subsequently fuse with early (EEA-1-positive) endosomes, from which the receptors can either traffic to late endosomes and the lysosomal compartment for degradation or recycle to the cell membrane. 31 This constitutive downregulation of growth factor receptors may serve 2 important purposes. First, it desensitizes the cell to avoid premature activation by growth factors. In particular, for CD34 ϩ stem cells, this may be essential to maintain plasticity during their trafficking from and toward BM niches. Second, when cells are recruited to sites of inflammation or tissue repair, targeted recycling is essential to generate polarity of the cells. Active recycling of KDR and CXCR4 to the leading edge may sensitize the cell to VEGFand SDF-1-induced chemotactic signals. 32 VEGF and SDF-1 play important roles as chemoattractants in progenitor cell mobilization and homing, and both factors may also serve as EC differentiation factors. 33, 34 Because VEGF and SDF-1 are actively released from activated platelets, the rapid upregulation of KDR and CXCR4 by CD34 ϩ cells that have adhered to platelet-rich sites of EC injury may well further stimulate these cells to enter an EC fate. 7 The fact that WM inhibited KDR expression indicates that recycling of this receptor is the result of PI3K-dependent signaling pathway(s) that follow on homing-mediated activation. It was previously demonstrated that ligation of PSGL-1 with a soluble form of P-selectin activated expression of the integrins MAC-1 (CD11b/CD18) and ␣v␤5. 7 Therefore, integrin-mediated "outside-insignaling" could be one mechanism responsible for the elevation of PI3K. 35 In addition, PSGL-1-ligation itself can lead to PI3K activation in an Src kinase-dependent pathway. 10 A third pathway that may lead to PI3K activation is exposure of the adherent CD34 ϩ cells to SDF-1 expressed by activated platelets. 36 By using FACS analysis, we determined that low levels of CXCR4 are present on freshly isolated CD34 ϩ cells (data not shown); on binding of SDF-1, the cells can be activated to a promigratory state in a PI3K-dependent fashion. 37 Finally, CD34 ϩ cell fractions have been administered in clinical trials aimed to develop cell-based strategies to treat patients with cardiac and peripheral ischemic disease. 38 
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